BACKGROUND
RAS mutations, as a group, are the most common oncogenic drivers of non-small-cell lung cancer (NSCLC), and they occur in approximately 30% of patients. Whether daraxonrasib (RMC-6236) - an oral RAS(ON) multiselective, tri-complex inhibitor of guanosine triphosphate-bound mutant and wild-type RAS protein iso...
K. Arbour, S. Punekar, Jia Luo et al.· New England Journal of Medic...· 1 citation
Recent clinical advances using RAS-targeted small-molecule inhibitors, including daraxonrasib, a RAS(ON) multi-selective, noncovalent, tri-complex inhibitor, has shown promising responses but are limited in durability for pancreatic ductal adenocarcinoma (PDAC). Preclinical studies indicate that RAS inhibition ca...
Zi-Rui Zhu, Benjamin C. Barrett, Aadi Bhattacharya et al.· Cancer Research· 0 citations
Despite shared genomic drivers with PDAC, ASQ exhibits transcriptionally distinct features with spatially organized tumor and immune heterogeneity, supporting the need for subtype-specific therapeutic strategies.
S. Haldar, Meredith Wetzel, Jia-Yun Lu et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.